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1. Introduction 
Melanoma is one of the most commonly diagnosed cancer during the childbearing age and 
during pregnancy. It is also the malignancy that is most often reported in the literature in 
association with placental and/or foetal metastasis (Alexander et al., 2003).  
The coexistence of melanoma and pregnancy is therefore not an exceptional situation, 
difficult to manage, raising numerous questions in terms of prognosis, feasibility of the 
different imaging and radio(diagnostic investigations, and of the various modes of 
treatment. On the other hand, when melanoma is diagnosed during the childbearing age, 
out of the immediate context of pregnancy, several questions are raised regarding the 
potential consequences on the evolution of melanoma of being pregnant later on.  
2. Epidemiological data 
Cancer is now among the leading causes of non(accidental death in women of child(bearing 
age. In the USA, malignancy accounts for about 19% of mortality in women aged between 15 
and 34 years (Pavlidis, 2002). The most frequently observed cancers among young women of 
child(bearing age are breast cancer, cervical cancer, malignant haemopathies (Hodgkin's 
disease and leukaemia) and melanoma (Langagergaard, 2011). 
In France, between 1980 and 2000, the standardized worldwide population incidence rate of 
melanoma increased from 3,9 to 9,5/100,000 persons/year among women. In 2000, the 
estimated number of new cases of skin melanoma was 7,231, with 58% diagnosed in women. 
The incidence increased by a factor of 3,2 among men and by a factor of 2,4 among women. 
Despite this greater increase among men, incidence remained higher among women across 
the whole period (Grange, 2005). In Denmark, for instance, the incidence of melanoma 
among women between the ages of 15 and 34 increased by 4,3% per year on average from 
1970 to 1999 (Van der Horst et al., 2006). Altogether, it is estimated that about one third of all 
melanomas in women is diagnosed during their childbearing years (Langagergaard, 2001). 
In Western countries, women often postpone childbearing for different reasons 
(Langagergaard, 2011) and because the incidence rates of most cancers increases with 
advancing age, more women can therefore be expected to be diagnosed with cancer before 
childbearing or during pregnancy. Although the exact incidence and prevalence are 
unknown, estimates suggest one to two new cases of cancer in every 1,000 pregnancies 
(Alexander, 2003). The most frequently encountered cancers during pregnancy are in line 
with those the most frequently described among young women of childbearing age: for 
breast and cervical cancer, the incidences estimated per number of pregnancies are of the 
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order of 1/2,000 to 1/10,000; for lymphomas, the incidence is estimated at 1/1,000 to 
1/6,000. The incidence of melanomas in pregnancy is estimated at 1/1,000 to 1/10,000, and 
melanoma is thought to amount to around 8% of cancers diagnosed during pregnancy 
(Oduncu et al., 2003). 
However, the real incidence of cutaneous melanoma occurring in pregnancy is still not 
known. Lens et al., 2004 examining the data from the Swedish National and Regional Cancer 
and Mortality Registries found that, among 19,337 women diagnosed with cutaneous 
melanoma in the period from 1958 to 1999, 28,6% were diagnosed with melanoma during 
their reproductive period, while only 0,9% of the women were diagnosed with melanoma 
during pregnancy. Stensheim et al., 2009 used the Cancer and Medical Birth Registry of 
Norway to assess 42,511 women (516 pregnant) aged to 16 to 49 with various cancers. The 
most commonly diagnosed cancer during pregnancy was melanoma. 
3. Melanoma and influence of hormonal factors 
For many years, there have been concerns that hormonal and immunological changes 
occurring during pregnancy may be important in the development of melanoma. Changes 
in pigmentation are associated with pregnancy, oral contraceptives and hormone 
replacement therapy. These observations have led to speculation concerning a relationship 
between hormones and melanoma. 
3.1 Exogenous female hormones 
Numerous epidemiological studies have questioned whether the use of oral contraceptives 
(OCs) or hormone replacement therapy (HRT) could increase a woman’s risk for melanoma. 
Risk is expressed as an estimate of relative risk (RR) or odds ratio (OR). OR is the odds of 
melanoma occurring in women exposed to OCs/ odds of melanoma occurring in those not 
exposed to OCs. These studies showed conflicting results: a recent case(control study of OCs 
and risk of melanoma (Koomen et al., 2009) suggests a cumulative dose(dependent 
increased risk of melanoma with the use of OCs: 778 cases and 4,072 controls were included; 
melanoma risk was significantly associated with estrogen use (≥ 0.5 year; adjusted OR= 1,42, 
95% CI 1,19(1,69). The major limitation of this study was the lack of information concerning 
sun exposure, skin type, sunburn history which are important potential confounders. 
However,  in their review of the literature, Gupta et al. (Gupta δ Driscoll, 2010) identify 22 
studies that have explored whether or not OCs enhance a woman’s risk for melanoma, and 
most have not shown an effect of use of OCs at some time in life compared with women 
who never used OCs. No studies have specifically reported the impact of OCs on prognosis 
for women diagnosed with melanoma. The data concerning HRT and melanoma risk are 
more limited than for OCs, but most of these studies have shown no effect of HRT (Gupta δ 
Driscoll, 2010).  
In summary, current clinical evidence does not suggest that exogenous female hormones 
contribute significantly to increased risk of melanoma. 
3.2 Endogenous female hormones 
The effects of high concentrations of oestrogen as a result of pregnancy on melanogenesis 
have long been debated, leading to different questions: is there an influence on melanoma 
prognosis if a woman is diagnosed with it during pregnancy? Should women with a 
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previous history of melanoma avoid subsequent pregnancies in order to limit the risks of 
local or systemic recurrences? 
3.2.1 Prognosis of melanoma diagnosed during pregnancy  
Many studies since the 1980s have investigated whether survival was impacted in women 
diagnosed during pregnancy with melanoma classified as localized stage I or II according to 
the American Joint Committee on Cancer, AJCC (Balch et al., 2001). Randomized or non 
randomized clinical trials to assess the implication of pregnancy in women with cutaneous 
melanoma do not exist. In the literature, there is population(based studies or consecutive or 
non(consecutive case series ; these studies assess survival rates between pregnant women 
with melanoma compared to age adjusted non pregnant women. Two recent population (
based studies addressed the question of whether pregnancy adversely affects survival in 
melanoma patients. Lens et al., 2004 reported on 185 patients from the Swedish Cancer 
registry who were pregnant at the time of diagnosis of localized melanoma. The outcome of 
these patients was compared with 5,348 non(pregnant age( and gender(matched controls. 
Multivariate regression analysis showed that pregnancy at the time of melanoma diagnosis 
was not a significant variable in relation to overall survival. Authors noted that pregnant 
melanoma patients had somewhat thicker melanomas, with a mean Breslow thickness of 
1,28 mm versus 1,07 mm in controls.  
A second population(based study (O’Meara et al., 2005) used the database from the 
California Cancer Center to evaluate “pregnancy(associated melanoma”, specified as a 
woman diagnosed with melanoma during pregnancy or within 1 year after delivery (post 
partum group). The control group was an age(matched group of patients who were not 
pregnant at the time of diagnosis. The median Breslow thickness was 0,77 mm in pregnant 
patients, 0,9 mm in post partum patients and 0,81 mm in the controls. O’Meara et al., 2005 
found no evidence of a decrease in survival of patients who were pregnant 
(HR=0,79;P=0.570) or post partum compared to controls. The size of the study population is 
a strength, but one limitation is that approximately 20% of the Breslow thickness data were 
missing for both the study and the control group and we cannot extrapolate therefore 
whether the groups were well balanced or not regarding this important prognosis marker. 
In the most recent population(based study, Stensheim et al., 2009 used the Cancer and 
Medical Birth Registry of Norway to assess 42,511 women (516 pregnant) aged to 16 to 49 
with various cancers. The cancer most commonly diagnosed during pregnancy was 
melanoma. When compared to age( and gender(matched non pregnant controls, there was a 
slightly increased cause(specific death rate if melanoma was diagnosed during pregnancy. 
No difference in Breslow index was found between the two groups; however the Breslow 
thickness was collected for only 55% of the pregnant patients. 
The details of the other studies and the results are presented in Table 1. Altogether, no 
statistically significant difference in survival rates between women diagnosed with 
melanoma during pregnancy and women diagnosed with melanoma out of pregnancy was 
established, suggesting that pregnancy does not favour the development of more aggressive 
melanoma. 
There are little data to address the question of whether pregnancy has a negative effect on 
survival in patients with more advanced disease. In a study reported by Shiu et al., 1976, 14 
patients with regional stage III AJCC melanoma diagnosed during pregnancy were found to 
have an important decrease in survival compared with 11 regional stage III AJCC melanoma 
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nulliparous patients. The 5(year survival was 29% for the pregnant patients and 55% for the 
control group, not statistically different, but very small numbers of patients were involved. 
We recently observed that the 2(year survival rate in 16 AJCC stage III patients diagnosed 
during pregnancy was 56% (Pagès et al., 2010), which is close to that reported in the 
literature for those not pregnant (Balch et al., 2001); the AJCC stage IV (6 patients) 2(year 
survival rate was 17% which was shorter than that reported in the literature (Balch et al., 
2001). Nevertheless, this data does not make it possible to draw definitive conclusions, on 
account of the small sample number and the absence of a control group in our study.  
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Reintgen
et al. 
1985 
58 585 
1,90/ 1,51 
 
NS 5 y (mean) 
McManammy
et 
al. 1989 
23 243 
 
1,62/ 1,72 
 
NS 2 mo(20 y 
Wong et al. 1989 66 619 
 
1,24/ 1,28 
 
NS NR 
Slingluff et al. 
1990 
100 86 
 
2,17/ 1,52 
 
NS 6 y (mean) 
MacKie et al. 
1991 
92 143 
 
2,38/ 1,96 
 
NA NA 
Daryanani et al. 
2003 
46 368 
 
2/ 1,70 
 
NS 
106 mo 
(median) 
Lens et al. 2004 185 5348 
 
1,28/ 1,07 
 
NS 
11,6 y 
(median) 
O’Meara et al. 
2005 
149 
Within 1 year 
postpartum: 263 
Non pregnant: 
2,451 
 
0,77/0,90/ 0,81 
 
NS 2(10 y 
Abbreviations: Mo: months; y: years; NA: not available, NS: statistically non(significant difference in 
survival rates between groups. 
Table 1. Controlled studies evaluating the impact of pregnancy on survival in women with 
AJCC stage I/II melanoma. 
www.intechopen.com




3.2.2 Impact of subsequent pregnancy on melanoma prognosis 
A small number of studies have addressed the impact of pregnancy after a diagnosis of 
melanoma. One of them (Lens et al., 2004) was a secondary analysis within a large 
retrospective cohort study of Swedish patients: 966 women who became pregnant after 
melanoma diagnosis were compared with 4,567 women without pregnancies subsequent to 
the melanoma diagnosis. A multivariable Cox regression model showed that pregnancy 
after melanoma diagnosis was not related to survival (Hazard Ratio for death in women 
who had pregnancy subsequent to the diagnosis of melanoma: 0.58, 95% CI= 0.32(1.05). 
Based on the current evidence, there is no reason to recommend deferral of subsequent 
pregnancy in women diagnosed with localized melanoma. Counselling women on 
subsequent pregnancies should be based upon well(known prognostic factors, such as 
Breslow thickness and ulceration (Balch et al., 2001). In women with thick tumours (over 1.5 
mm), it may be recommended to discuss with the patient the fact that if melanoma recurs it 
is more likely to do so in the first 2 years; physicians can thus advise these women to delay 
pregnancy for 2 to 3 years. 
Altogether, the issue of whether hormones influence malignant melanoma has been 
controversial for many years. There is no evidence that pregnancy adversely affects outcome 
in melanoma patients who have clinically localized disease. Continuing to recommend a 
postponement of childbearing for these patients is not supported by available clinical 
evidence suggesting an increased risk of cancer progression due to pregnancy itself. For 
more advanced disease, recommendations must be based on individual patients and their 
wishes. 
4. Maternal!foetal transmission of melanoma during pregnancy 
Only disseminating, metastatic cancers appear to be liable to produce placental and foetal 
metastasis, in an haematogenic way. The real incidence rates for placental and foetal 
metastasis, and the natural history of cancers during pregnancy, are still little known. In 
France, for instance, there are no epidemiological surveillance tools for cancers among 
pregnant women. In the literature, irrespective of type of cancer, about a hundred cases of 
placental metastasis (excluding cases of foetal origin and trophoblastic disease) have been 
described since 1866 (Dessolle et al., 2007). Alexander et al. in a literature review reported 87 
cases of placental metastasis secondary to maternal cancer. In this study, melanoma was the 
cancer the most frequently responsible for this type of development: 27 cases out of 87 
(31%). Given the possibility of placental metastasis, the placenta should be very carefully 
examined, both macroscopically and microscopically in case of metastatic melanoma in the 
mother. 
Furthermore, the placenta represents an ideal site for metastases during gestation, because 
of its vascularisation, its large surface area and its biological environment and also because 
of its hyperkinetic state associated with pregnancy.  
Table 2 sums up the cases of placental and/or foetal metastasis in connection with 
melanoma described in the literature and is an actualisation of the table presented in the 
paper of Alexander et al. Of the 27 placentas subjected to anatomo(pathological 
investigation, 17 cases of microscopic placental metastasis are reported, without any 
anomaly being macroscopically visible. The microscopic examination of the placenta should 
be as thorough as possible: in the case reported by Baergen et al, the placental metastatic 
localisations were visible on only 3 of the 50 sections performed, in the case reported by 
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Valenzano Menada et al. the microscopic examination with normal staining of the placenta 
showed no particular anomaly and the micro(metastases were only visualised by the mean 
of immuno(histo(chemical analyses (PS100). 
Considering now the problematic of foetal metastasis secondary to maternal cancer, 
according to the review of the literature by Dessolle et al, 15 cases have been published since 
1866. Several types of cancer have been incriminated: among the 15 cases, 5 foetal metastasis 
were secondary to maternal melanoma, 5 to acute leukaemia or lymphoma, 2 to bronchial 
cancer, 2 to sarcomas and one to a non(specified maternal cancer. Thus, although foetal 
metastasis in case of disseminated cancer in the mother is an exceptional situation, 
melanoma does appear as the most frequent cause. The study by Alexander et al. collates 6 
reports of foetal metastasis secondary to maternal metastatic melanoma. Two further cases 
of foetal metastasis (Trumble et al., 2005 and Valenzano Menada et al., 2010) have been 
further reported. Among these 8 cases (Weber et  al., 1930 Holland et al., 1949 Gottron et al., 
1940 Dargeon et al., 1950 Aronsson Cavel et al., 1963 Brodsky et al., 1965 Ferreira et al., 1998 
Trumble et al., 2005 Valenzano Menada et al., 2010), tumoral encroachment on the placenta 
was observed for 4. The 4 remaining cases were not examined in this respect. These 8 
observations, although some are incomplete, enable the following characteristics: 
 Melanoma metastasis appearance occurring shortly after birth, with a mean time lapse 
of around 3 months (age at diagnosis ranging from 1 day to 9 months, missing data for 
1 case). 
 Relatively homogeneous clinical presentation of metastatic proliferation to the child: the 
neonatal metastases were for the most part in the form of subcutaneous metastatic 
nodules, or intra(abdominal tumoral masses; there are exceptions for the cases 
published by Trumble et al. and Valenzano et al, where intracranial proliferations were 
diagnosed at 7 and 3 months after birth, respectively.  
 Extremely poor prognosis, as the large majority of the infants died before the age of 1 
year, with the exception of two cases (Aronsson, Cavell et al., 1963 and Valenzano 
Menada et al., 2010) of secondary regression of the metastatic disease in the children. In 
the case published by Aronsson and Cavell, spontaneous resolution of pulmonary and 
subcutaneous metastases occurred at 13 weeks after birth; the remission was 
secondarily confirmed during follow(up, with the child presenting no particular heath 
problem at the age of 14 years. Valenzano Menada et al. reported the case of a 
regression of intracranial and pulmonary metastases at 5 months after birth following 
initial failure of chemotherapy associating ifosfamide and adriamycine (1 month after 
discontinuation of chemotherapy). Complete remission of the disease was later 
confirmed when the child was seen at 24 months, with no residual signs of disease. 
 Predominance of male children: 6 cases out of 8, one girl and one stillborn child whose 
gender was not reported.  
5. Management of melanoma in a pregnant woman 
Diagnosing melanoma during pregnancy will raise several questions, depending notably of 
the stage of malignancy (primary melanoma, lymph node metastasis, visceral metastasis, 
type of visceral metastasis) and of the gestational age.  One of the first step will be the 
evaluation of the extent of the cancer and will raise the question of the feasibility of some 
radiological diagnosis procedures and another step will be the feasibility of the oncologic 
treatment (surgery, adjuvant therapy with immunotherapy, radiotherapy, chemotherapy…). 
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Weber et al., 1930, 
Holland et al. 
1949 
+/+ 2 m +/ 8 m Death 10.5mo 
Gottron et al., 
1940 
NE 2 m +/ NR Death 5 mo 
Dargeon et al., 
1950 
NE 4 d +/ 9 m Death 10 mo 
Aronsson et al. , 
Cavell et al., 1963 
NE 4 d +/ 2 m 
Melanoma 
Regression, 
Alive (14 years 
follow up) 
Brodsky et al., 
1965 
+/+ 17 d +/ 11 j Death 48 d 
Ferreira et al., 
1998 
+/+ 2 d +/ 1 j Stillbirth 
Trumble et al., 
2005 
NE NR +/ 7 m Death 25 mo 
Valenzano 
Menada et al., 
2010 
(/+ 15 d +/ 3 m 
Melanoma 
Regression 
Alive (24 mo 
follow up) 
Markus et al., 
1918 
+/+ 5 h No Death 1 d* 
Byrd et al., 1954  (/+ 21 d No Death j* 
Reynolds et al., 
1955 
(/+ 1 m No Alive/ 10mo 
Freedman et al., 
1960 
+/+ 1.5 m No Alive/ 24mo 
Stephenson et al., 
1971 
(/+ 3m No Alive/ 24mo 
Holcomb et al., 
1975 
(/+ 18 d No Alive/  3mo 
Sokol et al., 1976 +/+ 54 d No Death 2 d* 
Smythe et al., 
1976 
(/+ 20 d No Alive/ 9mo 
Gillis et al., 1976 +/+ 7.5 m No Alive/ 24mo 
Russel et al., 1977 +/+ 15 d No Alive/ 5mo 
Looi et al., 1979 (/+ 48 d No Alive/ 1mo 
Moller et al., 1986 +/+ 30 d No Alive/ 6mo 
Anderson δ 
Machin 1989 
(/+ 6 m No Alive/ 12mo 
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Brossard et al. 
1994 
(/+ 4 d No Alive/ 12mo 
Marsh et al., 1996 (/+ 21 d No 
Lost to follow 
up 
Dillman et al.,  (/+ 5 m No 
Lost to follow 
up 
Baergen et al. 
1997 
(/+ 7 d No Alive/ 7mo 
Dipaola et al., 
1997 
(/+ 1 m No Alive/ 17mo 
Jonhston et al., 
1998 
(/+ 4 d No Alive/ 12mo 
Merkus et al., 
1998 
(/+ 2 m No Alive/ 48mo 
Altman et al., 
2003 
(/+ 19 m No Alive/ 19mo 
Alexander et al., 
2004 
Pagès et al., 2010 
(/+ 
+/+ 
56 d 
3,5 m 
No 
No 
Alive/ 10mo 
Alive/ 56mo 
Abbreviations : NE: not examined, NR : not reported, d: days, mo: months , 
* : cause of death = prematurity. 
Table 2. Placental and/or foetal melanoma metastases. 
The question of the maternal prognosis will be central and the opportunity of pursuing or 
not the pregnancy will be asked by the patient, her family and the medical staff. 
5.1 Radiological diagnosis in pregnant women 
A recent review (Lazarus E. et al., 2007) pointed out a 121% increase over 10 years in the use 
of imagery investigations requiring ionizing radiation during pregnancy, with computed 
tomography (CT) increasing by 25% per year. In pregnancy, the use of the irradiating 
techniques of classic radiology should be strictly evaluated. The French 





	
	 recalls some principles: 
 In almost all cases, if a radiological diagnostic examination is considered medically 
necessary, the risk incurred by the mother of failure to perform such examination 
should be greater than the risk potentially incurred by the foetus. 
 The radiation doses resulting from most diagnostic procedures usually do not present 
serious risk of death, malformation or altered mental development of the foetus. If the 
foetus is in the direct radiation beam, the procedure can often be adapted so as to 
reduce the foetal dose. 
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 When an ionizing examination is indicated in the course of which the fœtus is to be in 
the direct beam, and when this examination cannot be postponed until after parturition, 
the dose delivered to the foetus should be minimised as far as possible.  
 In diagnostic radiology, the estimation of the radiation dose to the fœtus is generally 
not required, except when the fœtus is in the direct beam. 
Thus, in most cases, irradiating radiological procedures are feasible for diagnosis or 
assessment of the extent of a maternal cancer (Chen et al., 2008). It is considered that the 
threshold fœtal irradiation dose that is potentially teratogenic is of the order of 0,1 to 0,2 
Gray, Gy (Kal et al., 2005)). The radiation dose to the foetus from a typical CT study of the 
maternal pelvis is variable and depends on the gestational age and scanning parameters. 
The estimated dose of an investigation of this sort ranges from 0,024 Gy in the first trimester 
to 0,046 Gy in the third trimester (Pentheroudakis et al., 2006). Therefore, the radiation dose 
of the pelvis is likely to be below the estimated threshold level for inducing congenital 
malformations. Likewise, as mentioned by the International Radioprotection Commission, a 
foetal dose of 0,1 Gy is probably reached neither from 3 pelvic tomodensitometry 
examinations, nor from 20 conventional diagnostic radiographic examinations of the 
abdomen or pelvic area. In a review of the literature published by Pentheroudakis et al, the 
foetal doses received according to one or another type of ionising radiological examination 
performed on the mother are given, and estimated to be on average at 0,0004 mGy for chest 
radiography, 0,17mGy for chest tomodensitometry, and 18 to 25 mGy for abdominal(pelvic 
tomodensitometry. This information can be used to counsel pregnant patients who require 
investigation involving ionizing radiation. Nevertheless, a risk of carcinogenesis in the 
foetus after 
 irradiation always still, regardless of the dose. The baseline risk of fatal 
childhood cancer is 5 in 10.000 and the relative risk after exposure to 0,05 Gy is 2 (Chen et 
al., 2008); this relative risk may appear substantial but it should be remembered that the 
baseline risk is very low and that the 2004 Guidelines of the American College of 
Obstetricians and Gynecologists do not precisely indicate the estimated carcinogenic risk in 
case of irradiation 
  describing it as “very small” and it is concluded that it is 
exceptionally unlikely that any single diagnostic radiological examination would deliver a 
radiation dose sufficient to justify pregnancy termination. Numerous authors agree that it 
can be thought that radio(diagnostic examinations in pregnant women can be performed 
after appropriate evaluation of the risk/benefit ratio; however, it is generally the 
"substitution" rule that predominates, by way of endeavours either to delay the 
investigation to the post(partum period, or to obtain the information required by other 
means, avoiding ionisation. For instance, Nicklas et al., 2000 suggest a certain number of 
alternatives to the standard radiographic procedures in the context of metastatic cancer in 
pregnant women: the use of non ionising examinations such as chest and abdominal 
Magnetic Resonance Imaging (MRI), to look for deep nodal involvement and evaluation of 
the pulmonary and liver parenchyma as an alternative to chest and abdominal 
tomodensitometries, and cerebral MRI for the evaluation of the central nervous system. 
However, concerning MRI, the current guidelines of the U.S. Food and Drug Administration 
indicate that the safety of MRI with respect to the foetus « has not been established ». The 
risk incurred by the foetus during MRI examination without injection is on the one hand 
related to teratogenic effects, and on the other to the possible occurrence of damage to 
hearing. In view of the theoretical risk of foetal overheating/cavitation, first trimester MRI 
should be avoided (Chen et al., 2008) ; damaging effects could indeed arise from different 
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mechanisms, among which the thermal effect of magnetic resonance gradient changes and 
direct non(thermal interaction of the electromagnetic field with biological structures 
(Campbell FA et al., 2006). It should be noted that the 2007 American College of Radiology 
guidance document for safe MRI practices does not differentiate among the pregnancy 
trimesters and states that all pregnant patients can receive MRI as long as the “risk( benefit 
ratio to the patient warrants that the study be performed” (Kanal et al., 2007): MRI, thus, 
seems safe to use among pregnant women in the second and third trimesters. 
The injection of contrasting substances (iodine or gadolinium) for imagery investigations is 
also questionable during pregnancy. Iodine(based substances belong to FDA category B. 
This category includes molecules for which animal studies do not show any foetal risk but 
for which human studies are lacking, or molecules for which animal studies have shown 
damaging effects on the foetus but where this effect has not been confirmed by studies 
among pregnant women in the first trimester of pregnancy. In animals, regarding the use of 
iodine(based contrast substances, no teratogenic, abortive or mutagenic effect has been 
reported (Webb et al., 2005). However the agents pass through the placental barrier, 
allowing a risk of neonatal hypothyroidism (Webb et al., 2005). This risk is only really 
present from the 20th week of gestation, at the time when the thyroid starts to be functional. 
The screening for neonatal hypothyroidism is in practice an examination that is carried out 
systematically by paediatric teams, but the importance of ensuring that this is indeed carried 
out among infants exposed 
  to iodine(based contrast substances should be 
emphasised (Chen et al., 2008). 
Regarding the injection of gadolinium chelate, this is not at present authorised during 
pregnancy; intravenous gadolinium is teratogenic in animal studies, albeit at high and 
repeated doses (Chen et al., 2008). Gadolinium is classified as a category C drug by the U.S 
Food and Drug Administration but can be used if considered critical. In humans, knowledge 
on this subject relies on isolated clinical cases or small series showing no teratogenic effect 
(Lin et al., 2007). For instance, Marcos et al., 1997, report a series of 11 pregnant patients at 
terms ranging from 16 to 37 gestation weeks, who underwent MRI with gadolinium 
injection (gadopentatate dimeglumine: 0.1mmol/kg) for the purpose of evaluating a 
placental pathology, and no adverse effect was reported among the neonates. Likewise, in a 
prospective series of 26 pregnant patients exposed in the first trimester of pregnancy to MRI 
with gadolinium injection, de Santis et al., 2007, observed no abnormalities among the 
neonates overall. However, data is as yet insufficient in humans to justify concluding to the 
fact that the use of gadolinium among pregnant women is without risk for the foetus. 
In practice, when there is an issue regarding whether or not investigations can be carried out 
for tumoral extension in pregnant women, the indications for the different examinations 
should be discussed one by one, taking into account the gestational stage, the anatomical 
area to be explored and the sensitivity of the considered radiodiagnosis tests. For instance, 
MRI, after injection of gadolinium chelate, is the most sensitive method for the detection of 
intracranial metastasis (Naggara et al., 2006)). However, as previously mentioned, the use of 
this contrast agent is not authorised in pregnant women. Therefore, in order to decrease the 
risk of false negatives, a brain scan with injection will have to be preferred to cerebral MRI 
without injection to look for cerebral metastases during pregnancy. Regarding the 
exploration of the chest, it was seen above that some authors recommend thoracic MRI. This 
technique is very sensitive for the exploration of the mediastinum, the heart or the rachis 
(Thompson et al., 2000)) but for the exploration of the pulmonary parenchyma, thoracic CT 
remains the first(line examination, even among pregnant women (Pentheroudakis et al., 
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2006). This can be backed up if necessary, beyond the first trimester of pregnancy, by 
abdominal(pelvic non(injected MRI. 
Therefore, although there is no general agreement regarding the initial investigations for 
metastatic melanoma during pregnancy, in terms of the risk / benefit balance, the 
association of contrast(enhanced brain and chest CT scan with abdominal ultrasonography 
can be proposed (Pagès et al., 2010). 
5.2 Sentinel lymph node procedure and pregnancy 
The sentinel node is the first lymph drainage node invaded from the primary tumour. 
Sentinel lymph node biopsy (SLNB) is carried out in order to determine the presence or 
absence of lymph(node micro(metastases in a patient without clinical adenomegalia. For 
melanoma, SLNB is currently considered as a staging procedure, that can be offered to the 
patient. In practice, the detection of sentinel node encroachment is performed by injection of 
a Technetium(labelled radiocolloid (isotopic method) in the area of the excision of the 
primary melanoma, generally the day before surgery. This injection can be coupled with a 
vital blue staining (colorimetric method). If the sentinel node shows micro metastasis, 
lymph node dissection is at present recommended.  
In the literature, some publications have attempted to assess the foetal dose received during 
SLNB in non(pregnant women, using devices so as to mimic the different stages of 
pregnancy as close as possible. Thus, Gentilini et al., 2004 report a series of 26 non(pregnant 
patients with breast cancer and candidates for SLNB. This consisted in peri(tumoral 
injection of about 12 Mbq of nanocolloid 99m Tc(HAS before surgery; thermoluminescent 
dosimeters were positioned at the injection site, between the injection site and the 
epigastrium, and in three other locations mimicking the position of the foetus in the 
different trimesters of pregnancy:  epigastrium, umbilicum, and hypogastrium. The 
scintigraphic images showed no diffusion of the radiographic marker except at the injection 
point and in the sentinel node. In 23 of the 26 patients, all the measures of absorbed doses 
were below the dosimeter detection thresholds. For 3 patients, the doses absorbed in the 
epigastric, umbilical and hypogastric areas were within the following ranges: 40(320; 120(
250; 30(140 UGy. The authors concluded that the foetal doses absorbed during the SLNB 
were negligible and that this procedure could therefore be used in pregnant women, on 
condition that a standardised protocol was developed. In a retrospective series of 9 patients 
(3 breast cancers, 6 melanomas) in whom the sentinel node procedure was performed in the 
course of pregnancy, Mondi et al. 2007 observed no neonatal abnormality among the 
newborns, while in 22% of the cases the procedure occurred in the first trimester of 
pregnancy. Thus the SLNB appears feasible in pregnant women, exposing the foetus to a 
negligible level of irradiation and hence to minimum risk. However, the concomitant use of 
methylene blue is still the subject of controversy in the literature, counter(indicated for some 
authors (Pentheroudakis et al., 2010), and envisaged for others (Pruthi et al., 2011). On the 
other hand, since SLNB can not currently be considered as a standard of care, except for 
accurate staging purpose, its realization in melanoma pregnant patient should be carefully 
questioned, with clear information delivered to the patient. 
5.3 Treatment of melanoma during pregnancy 
The optimal therapeutic strategy should be jointly discussed by the medical team, the 
patient and her family and will depend on gestational age, stage of cancer, treatment 
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options and patient wishes. It ideally requires a multidisciplinary approach with an 
obstetrician, a neonatologist, a medical oncologist, a surgeon and a psychologist. We will 
expose below the feasibility of the different therapeutical approaches usually used in 
melanoma during pregnancy: surgery, radiotherapy, immunotherapy and chemotherapy. 
5.3.1 Surgery 
Surgery in the course of pregnancy is not an exceptional occurrence. It is estimated that in 
the USA 1 to 2% of pregnancies will entail surgical intervention for non(obstetric purposes 
at some time in gestation (Kuczkowski et al., 2004). Risks to the foetus during surgery are 
not only anaesthesis(related, they also include intraoperative complications such as hypoxia 
and hypotension (Moran et al., 2007). Furthermore, decreased placental perfusion secondary 
to long(term positioning of the mother in the supine position is a mechanical problem in late 
pregnancy. Some physiological changes occurring in pregnancy have a direct impact on 
anaesthesic procedures, for instance : 
( the total body water and plasma volume increase by about 50%, resulting in an increase 
in the distribution volume of hydrosoluble drugs, thus modifying their pharmaco(
kinetic,  
( with the increase in volume of the uterus during pregnancy, there is a decrease in the 
return of blood via the lower vena cava, and a risk of aortic(caval syndrome, depending 
on the patient's position during surgery (dorsal decubitus) which can lead to severe 
maternal hypotension with serious consequences on the foetus, 
( gastro(intestinal motility is classically reduced during gestation with a relaxing of the 
lower oesophagal sphincter, presenting increased risk of inhaling gastric fluid during 
intubation under general anaesthetic. 
The surgeon and the anaesthetist should take into account all these alterations at the time of 
surgery in order to avoid secondary effects on mother or foetus as far as possible. Maternal 
and foetal monitoring should be set up as early a possible by a trained team. Mazze δ 
Kallen, 1989 examined adverse outcomes after non(obstetric operations during pregnancy 
(data from 3 Swedish health care registries from 1973 to 1981); there were 5,405 operations in 
the population of 720,000 pregnant women. The incidences of congenital malformations and 
stillbirths were not increased in the offspring of women having an operation. However, the 
incidences of very( low and low( birth weight were higher in the population having surgery 
and attributed to the underlying cause of the emergency of surgery during pregnancy. 
Commonly(used anaesthetics, including nitrous oxide, enflurane and narcotics, have been 
extensively used safely in pregnancy (Rosen, 1999). Most authors agree that anaesthesia 
(general, regional or local) can be administered to pregnant women without damaging 
effects on the development of the embryo or fœtus. (Moran et al., 2007) With modern 
surgical and anaesthesia techniques, the maternal death rate is negligible and surgery 
during the first trimester does not appear to increase the incidence of major birth defects.  
For localized melanoma, as in non pregnant patient, surgery is the mainstay of treatment for 
pregnant patients. With local anesthesia, local resection can occur whatever the trimester 
without increased risk (Richards δ Statsko, 2002). Concerning teratogenicity of local 
anesthesia, when administered to pregnant rats, it did not result an increased incidence of 
congenital malformations or adverse outcomes (Fujinaga δ Mazze, 1986). In a study of 34 
pregnant women having cutaneous surgery, Gormley et al., 1990 found no maternal or 
neonatal adverse events in 23 mothers who were available for follow up. However, in view 
of the absence of adequate clinical studies in humans, it is classically recommended (when 
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possible and excluding emergencies) to avoid surgical interventions in the first trimester of 
pregnancy, or even to postpone it until after childbirth, in accordance with risk(benefit 
trade(off and precautionary principles, assessed for each individual case. In regard to 
melanoma during pregnancy, cautious but definitive treatment is recommended. 
5.3.2 Adjuvant therapy with Interferon α 
Patients who are at higher risk for recurrence after definitive surgery (those with thicker 
primary tumors and/or with primary tumor ulceration and those with lymph node 
involvement) should be considered for adjuvant therapy (Kirkwood et al., 1996). Interferon 
–α(2b (IFNα2b) is the only effective adjuvant therapy for these patients that has been 
approved by regulatory authorities worldwide. The safety of IFNα2b during pregnancy has 
not been studied formally, however low to moderate doses of interferon alpha have been 
safely administered in pregnant patients with chronic myeloid leukemia, CML (Regierer et 
al., 2006; Mesquita et al., 2005). In their review of literature, Azim et al., 2010, reported 26 
CML patients exposed to IFN α during the course of pregnancy (one third during the first 
trimester). No congenital abnormalities were reported. Authors suggest that is probably due 
to IFNα high molecular weight, making it unlikely to cross the placenta. Egberts et al., 2006 
reported no specific birth defects in children born to mothers receiving IFNα 2b for 
melanoma. It seems that IFN α can be safely administered throughout the course of 
pregnancy, however the potential for severe toxicity and the marginal improvement with 
this regimen for melanoma make its administration during pregnancy inadvisable.  
5.3.3 Radiation therapy 
Exposure to ionising radiation 
 entails a certain number of risks, and these latter vary 
according to the foetal dose received and the gestational age at the time of irradiation of the 
mother. The real dose received by the foetus depends on the size of the field irradiated, the 
anatomical irradiated site, the distance of the embryo or foetus from the irradiated site and 
the total dose prescribed. Regarding the gestational age, classically, three periods are 
distinguished: 
( the so(called implantation period corresponding to the first 10 days after conception. 
During this phase, the "all or nothing" rule applies, terminating either in the loss of the 
embryo, or in the absence of any damage. Doses ranging from 0,05 to 0,15 Gy have been 
reported to increase the death rate 
  in studies on rats and mice (Roux et al., 
1983). 
( the embryogenesis or the organogenesis phase, from the 9th day to the 8th week, which 
involves risk of foetal malformation. These risks are related to a threshold dose of 
irradiation (Kal et al., 2005). Before the explosion of the atomic bomb, knowledge of 
radiation risks in humans relied on cases reported of pelvic irradiation in pregnant 
women. Thus Dekaban et al., 1968 conducted a review of the literature of published 
cases between 1921 and 1956 of pelvic irradiation among pregnant women, covering 
different terms in pregnancy (ranging from the 4th to the 25th week of amenorrhea 
(WA)). Twenty(six cases were analysed, with a wide variety of received doses, but, for 
the most part, above 2,5 Gy. Twenty children aged 3 months to 16 years were alive at 
the time of the last clinical examination. After exposure between the 4th and the 11th 
WA, numerous congenital abnormalities were reported: microcephaly, skeletal 
malformations, malformation of the genital organs, of the eyes (cataract, 
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microphthalmia, pigmentary degeneration of the retina) and damage to the central 
nervous system (severe mental retardation). The most frequent malformations observed 
among children exposed 
 in Hiroshima and Nagasaki was microcephaly (Stovall 
et al. 1995). 
( the period of foetal maturation and growth, from the 8th week to the end of gestation. 
At this stage, the organogenesis process is complete, but the CNS and the gonads 
continue to differentiate and are therefore more vulnerable to irradiation. During this 
period, the main ionising radiation risks 
  are intrauterine growth delays and 
severe mental retardation (Otake et al., 1996). 
It is however important to note that for foetal doses of 0,1 Gy, the spontaneous incidence of 
mental retardation, which is basically estimated to be 3%, is greater than the potential effect 
of radiation on the decrease in Intelligence Quotient (Streffer et al., 2003). In contrast, for 
foetal doses of 1 Gy, between the 8th and 15th WA, the probability of  decrease in 
IQ and mental retardation resulting from this, could be around 40%, thus superior to the 
spontaneous incidence (Kal et al., 2005). 
In practice, after consideration of all the potentially deleterious effects for the foetus, it is at 
present agreed that the maximum dose should not exceed 0,1 Gy on a gravid uterus (Kal et 
al., 2005). Pregnancy termination in case of doses received below 0,1 Gy is therefore not 
justified on the basis of the irradiation risk (Pentheroudakis et al., 2010) 
The other risk from irradiation 
, independently of the term of pregnancy, is the one 
of development of solid cancers and leukaemia among children born to irradiated mothers. 
The spontaneous incidence of cancers and leukaemia in children aged 0 to 15 is estimated at 
2(3/1,000 (Kal et al., 2005). The scale of the risk after low dose radiation and the variation of 
this risk according to pregnancy stage, have been the subject of numerous publications, but 
the interpretation of the data is still a subject of controversy. Most authors agree that 
prenatal exposure to ionising radiation at a dose of 0,01 Gy could increase the incidence by 
40% (to reach 3(4 per 1,000) (Kal et al., 2005). It is however possible to envisage medical 
radiotherapy procedures in pregnant women, on condition that the foetal dose is kept to a 
minimum. The following recommendations should be applied: 
( First, conduct an 
 evaluation of the dose received by the foetus. This modelling 
process is based on the use of phantoms and, for data collection, on the use of 
thermoluminescence dosimeters. 
( Secondly,
depending on these latter results, set up the devices aiming to minimise the 
foetal dose. Useful techniques for the minimisation of foetal radiation exposure include 
the use of lead shielding and modification of radiotherapy techniques, including the use 
of multileaf collimators reducing the field size and modifying the beam energy. 
( Thirdly,
perform 
 dosimetry. 
Thus, numerous authors consider that radiotherapy can be envisaged in the course of 
pregnancy, in particular in certain situations such a breast cancer, supra(diaphragm 
Hodgkin's disease, some primary and secondary cerebral tumours, and some head and neck 
tumours. Indeed, as an example, the irradiation of the breast in the course of pregnancy 
exposes the fœtus to around 0,1 to 0,3% of the total dose (total dose estimated: 50 Gy) 
(Antypas et al., 1998). Luis et al. published in 2009 a review of the literature on radiotherapy 
administered during pregnancy, grouping their series of 9 patients with 100 cases described 
in the literature, irrespective of cancer type, since 1950 (sources Cochrane, Medline, 
PubMed). These cases excluded radiotherapy for tumour in the pelvic area, and cases of 
combined chemo(radiotherapy during pregnancy. Among these 109 cases, there were 13 
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adverse outcomes: 2 spontaneous abortions, 5 perinatal deaths, 1 stillbirth, 1 sensorineural 
hearing loss, 1 case of undescended testis and ventricular septal defect, 1 case of learning 
difficulties, 1 case of hypospadias and 1 case of delayed development. The estimated fœtal 
dose was reported for only 4 cases, and was below 0,1 Gy, the threshold dose thought to 
apply for the appearance of radio(induced fœtal malformation. The authors underline that 
at doses estimated to be under 0,1 Gy for 
 foetal exposure, the occurrence of fœtal 
malformations cannot be distinguished from the background rate of spontaneous congenital 
abnormalities. When possible, an extended follow(up of patients and their offspring should 
be undertaken ; in the same review of the literature, Luis SA et al. report a median duration 
of follow(up of 37 months (maximum follow(up : 372 months). 
Although the important role of radiotherapy in achieving locoregional control and palliation 
in oncology is well recognised, this approach is not always incorporated into the 
management of melanoma. In general, patients with stage I(III melanoma (confined to the 
primary site and regional lymph nodes) are treated surgically with curative intent; in most 
cases, no further local treatment is needed. For stage IV melanoma, radiotherapy has an 
important role in the palliation of many symptoms (bleeding, pain, spinal cord compression 
from vertebral metastasis…) caused by recurrence or metastasis. Furthermore, for a few 
brain metastases, patients can be treated by neurosurgical resection or stereotactic 
irradiation. Whole brain radiotherapy after either stereotactic radiosurgery or surgical 
excision remains controversial (Patel et al., 2010). In most of cases, brain melanoma 
metastases are multiple and in this setting, high dose steroids and whole brain radiotherapy 
are frequently associated and provide temporary relief of symptoms (Cranmer et al., 2010). 
We reported 2 cases of radiotherapy during pregnancy for cerebral metastases of melanoma 
(Pagès et al., 2010). In the first case, a whole brain radiotherapy was associated with 
chemotherapy (fotemustin) during the second and third trimesters; in the second case, brain 
gamma knife stereotactic radiosurgery was performed as a single treatment at 23 WA for 3 
cerebral metastases. The fetal dose was estimated for only the 2nth case with 
thermoluminescent dosimeters put on epigastrium and in vagina and was between 0,02 and 
0,04 Gy for a maximum tumour dose of 20 Gy; the fetal exposure was less than 0,1 Gy, a 
dose below the deterministic threshold. No morphological abnormalities were observed in 
the two newborns with a follow(up of respectively 23 and 2 months. Several case series (Yu 
et al., 2003; Magné et al., 2001) have reported the birth of healthy babies from mothers who 
received radiotherapy for cerebral metastases. 
5.3.4 Chemotherapy  
Malignancy during pregnancy poses special challenges because of the conflict between the 
need to optimally treat the mother, while minimising risk to both mother and fœtus. The 
mother should be properly counselled so that she can reach an informed decision. The risks 
incurred by the foetus differ according to the moment of the exposure: indeed, the 
instatement of chemotherapy in the first trimester of pregnancy entails the risk of foetal 
death 
, spontaneous miscarriage and congenital malformation (teratogenicity). In the 
course of the second and third trimesters, the risks are different, mainly prematurity and 
intra(uterine growth retardation. The risk incurred also varies with the molecule used. 
Fotemustine and dacarbazine are two molecules belonging to the alkylating agent group, 
frequently used in the treatment of metastatic melanoma. Their use in pregnant women has 
been the subject of only a few publications in the literature. Since the 1960s, 37 cases of 
administration of dacarbazine to pregnant women have been reported, of which 8 
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concerned the first trimester (Table 3). Two neonates exposed during the first trimester 
presented congenital malformations: hypoplasia of the left thumb and bilateral agenesis of 
the metacarpals in the case reported by Dilek et al; microphthalmia and severe 
hypermetropia in the case reported by Li et al.
(Table 3). The imputability of dacarbazine in 
these malformations was nevertheless hypothetical, since the drug had been administered in 
both cases in association with other cytotoxic agents. Among the 29 infants exposed 
 
to dacarbazine in the second and third trimesters of pregnancy (Table 4), no congenital 
malformation was noted and nearly 50% were born prematurely, which is a significantly 
high proportion in comparison to prematurity rates in France in 2003, of the order of 7% 
(Bourillon, 2005). Nevertheless, we can not exclude that the alterated general health status of 
the mother take an important part in the high rate of prematurity observed. Likewise, in the 
general population, spontaneous abortion ranges from 10 to 20% while 3(4% of live birth 
suffers congenital anomalies (New York State Department of Health. Congenital 
Malformation Registry 1995 – annual Report); it is important to consider this information in 
the interpretation of the outcome of pregnant cancer patients treated during gestation. 
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Zemlickis et 
al., 1992 
1 Melanoma Dacarbazine TA NA NA 
Avilès et al., 
1991 
4 
Hodgkin's 
disease 
ABVD 
37 
38 
40 
40 
No 
All alive 
(4(14 years) 
Dilek et al., 
2006 
2 
Hodgkin's 
disease 
ABVD NR 
Yes, 1 case 
hypoplasia of 
the left thumb 
and bilateral 
agenesis of the 
metacarpals 
NR 
Li et al., 
2007 
1 Melanoma 
Cisplatin, 
carmustin, 
dacarbazine, 
tamoxifen 
34 
Micro(
phthalmia, 
hypermetropia 
 
Alive 
(1 year) 
Abbreviations : ABVD : adriamycin, bleomycin, vinblastine, dacarbazine, WA : weeks of amenorrhea, 
TA: therapeutic abortion, NA: not applicable, NR: not reported 
Table 3. Cases reported of administration of Dacarbazine during the first trimester of 
pregnancy. 
The series published by Avilès et al.  provides a relatively long follow(up of children 
exposed 
 to dacarbazine administered with other chemotherapy agents: the median 
follow(up was 9 years (range 3(16 years). The development of these 10 children, in terms of 
stature and weight, was considered normal in comparison with a control group of the same 
age and from the same socio(cultural environment. Likewise, no case of delayed psycho(
motor development was observed: all the children entered normal schooling when the time 
came; the results of IQ tests showed no significant differences with the control group. 
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Avilès et 
al., 1991 
6 
Hodgkin's 
disease 
ABVD 
38 
34 
35 
37 
38 
36 
No 
All healthy. 
(median 
follow(up: 9 y) 
Cardonick 
et al., 2004 
9 
Hodgkin's 
disease 
ABVD NR No 
Healthy 
(median 
follow(up:5 y) 
Lishner et 
al.1992 
4 
Hodgkin's 
disease 
ABVD NR No NR 
Hill et al., 
1974 
1 Melanoma Dacarbazine NR No 
Healthy 
(3 y) 
Toussi et 
al., 1974 
1 Melanoma Dacarbazine 32 No 
Healthy 
(3 y) 
Harkin et 
al.,1990 
1 Melanoma Dacarbazine 38 No 
Healthy 
(4 y) 
DiPaola et 
al.,1997 
1 Melanoma 
Cisplatin, 
dacarbazine, 
carmustin, 
tamoxifen 
30 No 
Healthy 
(1 y) 
Dilek et al., 
2006 
1 
Hodgkin's 
disease 
ABVD IUFD (36) NR NA 
Jonsthon et 
al., 1998 
1 Melanoma Dacarbazine 31 No 
Healthy 
(1 y) 
Pagès et al., 
2010 
3 Melanoma Dacarbazine 
36 
37 
26 
Yes 
(n=1) 
Healthy 
(median 
follow(up: 8 
m) 
Gottschalk 
et al., 2009 
1 Melanoma 
Dacarbazine, 
cisplatin 
28 Yes NR 
Abbreviations: ABVD: adriamycin, bleomycin, vinblastine, dacarbazine, IUFD : intra(uterine foetal 
death, IUGR : intra(uterine growth retardation, NR : not reported, NA : not applicable, Y: years, M: 
months 
Table 4. Cases reported of administration of Dacarbazine during second and third trimesters 
of pregnancy. 
Thus, present knowledge concerning the use of dacarbazine in pregnant women is sparse, 
based on isolated clinical cases or small series, and in the majority of cases dacarbazine was 
administered as part of poly(chemotherapy. All these elements make it difficult to 
determine the risk associated specifically with the use of this molecule. 
Regarding fotemustin, we reported a case of  administration in the second and third 
trimesters of pregnancy in a patient aged 28 followed for a stage IVM1C melanoma, together 
with whole brain radiotherapy. On account of a marked degradation in the general 
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condition of the mother and significant intra(uterine growth retardation, the delivery was 
induced at 30 WA, giving birth to a female child weighing 820 grammes, with no notable 
malformation or sign suggesting metastatic localisations; the placenta was free of 
metastases; at 23 months, the child was alive and well.  
In conclusion, dacarbazine and fotemustin should not be electively started during the first 
trimester of pregnancy, but these drugs can be administered during the second and third 
trimesters with reasonable safety, although there is an increased risk of stillbirth, growth 
retardation and premature delivery. The follow(up of these children is an important issue. 
Indeed, in the literature, the follow(up of children exposed 
 to chemotherapy is often 
too short and therefore the risk of secondary malignancy is likely to be underestimated. 
6. Conclusion 
The diagnosis of melanoma in the course of pregnancy is not an exceptional situation, and 
the provision of treatment in the case of advanced melanoma in pregnant women raises 
certain issues that are at once medical, ethical and philosophical. While in previous decades, 
pregnancy in patients with cancer was discouraged, currently such pregnancies are treated 
with more optimism; however, a right balance has to be found between the risks for the 
mother and those for the foetus.  This particular situation requires a multidisciplinary 
approach involving, among others, surgeons, oncologists, paediatricians, gynaecologists, 
obstetrician and radiotherapists. Despite the lack of published guidelines, most of the 
conventional treatment strategies appear to be feasible in the second and third trimesters of 
pregnancy with appropriate protection measures. International collaboration is required in 
order to collect data on a sufficient numbers of births among women with cancer in order to 
obtain more precise risk estimates for adverse infant outcomes. A long(term follow(up of 
these children born to women with cancer should also be established and documented.  
The information given to the mother and her family should be clear and honest, and in line 
with present scientific knowledge, not only concerning the possible damaging effects on the 
fœtus of any given substance, but also on the possible transmission of cancer to the child, in 
particular in case of advanced maternal melanoma. The prognosis of the disease, and the 
possibility that the child might have to grow up without his mother, should also be brought 
up.  
The arrival of innovatory therapies in the area of advanced melanoma, such as 
immunotherapy with anti(CTLA4 antibodies (ipilimumab) or targeted therapies (anti BRAF, 
anti MEK) constitute a revolution in the care of these patients and raise genuine hopes in 
terms of prognosis. If these hopes are confirmed, dealing with these drugs during 
pregnancy will be our tomorrow challenge.  
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